Literature DB >> 21753159

Olfactory dysfunction in LRRK2 G2019S mutation carriers.

R Saunders-Pullman1, K Stanley, C Wang, M San Luciano, V Shanker, A Hunt, L Severt, D Raymond, L J Ozelius, R B Lipton, S B Bressman.   

Abstract

BACKGROUND: Olfactory dysfunction is an established nonmotor feature of idiopathic Parkinson disease (PD), which may precede disease onset. Olfaction is likely disturbed in patients with PD with leucine-rich repeat kinase (LRRK2) G2019S mutations, although the degree of impairment is debated. It is also unclear whether mutation carriers who have not yet manifested with PD have olfactory disturbances.
METHODS: Thirty-one subjects with LRRK2 G2019S mutation-related PD (PD-manifesting carriers [PD-MC]), 30 subjects with PD without mutations (PD noncarriers [PD-NC]), 28 mutation carrier family members (nonmanifesting carriers [NMC]), and 46 controls completed the University of Pennsylvania Smell Identification Test (UPSIT). Generalized estimating equations were applied to determine whether olfactory score was associated with PD and LRRK2 mutation status.
RESULTS: As expected, having PD was associated with impaired olfaction regardless of LRRK2 mutation status. More importantly, however, impaired olfaction was increased overall in LRRK2 carriers both with and without PD, though the impairment was only present in a subset of NMCs. Compared to controls, the mean score was lower among NMC (difference = -3.518, p = 0.006), MC (difference = -7.677, p < 0.0001), and idiopathic PD (PD-NC) (difference = -13.810, p < 0.0001). Olfaction was better among MC (PD-MC) than non-LRRK2 PD (PD-NC) (difference = 6.13, p = 0.0012). Group differences from the continuous analysis were maintained in dichotomous analysis stratifying at 15th percentile for age and gender.
CONCLUSION: Olfaction is impaired in LRRK2 G2019S-mutation related PD, although less overall than other PD. Further, olfaction is impaired in a subset of LRRK2 NMC, suggesting that olfaction may be a marker for development of PD in this group, and that longitudinal studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21753159      PMCID: PMC3140803          DOI: 10.1212/WNL.0b013e318227041c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

1.  Olfactory loss may be a first sign of idiopathic Parkinson's disease.

Authors:  Antje Haehner; Thomas Hummel; Cornelia Hummel; Ulrike Sommer; Susann Junghanns; Heinz Reichmann
Journal:  Mov Disord       Date:  2007-04-30       Impact factor: 10.338

2.  Association of olfactory dysfunction with risk for future Parkinson's disease.

Authors:  G Webster Ross; Helen Petrovitch; Robert D Abbott; Caroline M Tanner; Jordan Popper; Kamal Masaki; Lenore Launer; Lon R White
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422

3.  The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations.

Authors:  Ozlem Goker-Alpan; Grisel Lopez; Joseph Vithayathil; Joie Davis; Mark Hallett; Ellen Sidransky
Journal:  Arch Neurol       Date:  2008-10

4.  Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.

Authors:  L Silveira-Moriyama; L C Guedes; A Kingsbury; H Ayling; K Shaw; E R Barbosa; V Bonifati; N P Quinn; P Abou-Sleiman; N W Wood; A Petrie; C Sampaio; J J Ferreira; J Holton; T Revesz; A J Lees
Journal:  Neurology       Date:  2008-09-23       Impact factor: 9.910

5.  G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Authors:  Carles Gaig; María José Martí; Mario Ezquerra; Maria Jesús Rey; Adriana Cardozo; Eduardo Tolosa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-08       Impact factor: 10.154

Review 6.  The genetics of Parkinson disease: Implications for neurological care.

Authors:  Christine Klein; Michael G Schlossmacher
Journal:  Nat Clin Pract Neurol       Date:  2006-03

7.  Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.

Authors:  L N Clark; Y Wang; E Karlins; L Saito; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2006-10-18       Impact factor: 9.910

8.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Authors:  Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood
Journal:  Lancet Neurol       Date:  2008-06-06       Impact factor: 44.182

9.  High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.

Authors:  Joaquim J Ferreira; Leonor Correia Guedes; Mário Miguel Rosa; Miguel Coelho; Marina van Doeselaar; Dorothea Schweiger; Alessio Di Fonzo; Ben A Oostra; Cristina Sampaio; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

10.  The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.

Authors:  Jeanne C Latourelle; Mei Sun; Mark F Lew; Oksana Suchowersky; Christine Klein; Lawrence I Golbe; Margery H Mark; John H Growdon; G Frederick Wooten; Ray L Watts; Mark Guttman; Brad A Racette; Joel S Perlmutter; Anwar Ahmed; Holly A Shill; Carlos Singer; Stefano Goldwurm; Gianni Pezzoli; Michela Zini; Marie H Saint-Hilaire; Audrey E Hendricks; Sally Williamson; Michael W Nagle; Jemma B Wilk; Tiffany Massood; Karen W Huskey; Jason M Laramie; Anita L DeStefano; Kenneth B Baker; Ilia Itin; Irene Litvan; Garth Nicholson; Alastair Corbett; Martha Nance; Edward Drasby; Stuart Isaacson; David J Burn; Patrick F Chinnery; Peter P Pramstaller; Jomana Al-hinti; Anette T Moller; Karen Ostergaard; Scott J Sherman; Richard Roxburgh; Barry Snow; John T Slevin; Franca Cambi; James F Gusella; Richard H Myers
Journal:  BMC Med       Date:  2008-11-05       Impact factor: 8.775

View more
  25 in total

Review 1.  Olfaction in Parkinson's disease and related disorders.

Authors:  Richard L Doty
Journal:  Neurobiol Dis       Date:  2011-12-20       Impact factor: 5.996

2.  Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.

Authors:  Anat Mirelman; Roy N Alcalay; Rachel Saunders-Pullman; Kira Yasinovsky; Avner Thaler; Tanya Gurevich; Helen Mejia-Santana; Deborah Raymond; Mali Gana-Weisz; Anat Bar-Shira; Laurie Ozelius; Lorraine Clark; Avi Orr-Urtreger; Susan Bressman; Karen Marder; Nir Giladi
Journal:  Mov Disord       Date:  2015-03-21       Impact factor: 10.338

3.  Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant.

Authors:  Rachel Saunders-Pullman; Roberto Angel Ortega; Cuiling Wang; Deborah Raymond; Sonya Elango; Katherine Leaver; Nikita Urval; Viktoriya Katsnelson; Rachel Gerber; Matthew Swan; Vicki Shanker; Roy N Alcalay; Anat Mirelman; Michael C Brumm; Helen Mejia-Santana; Christopher S Coffey; Kenneth Marek; Laurie J Ozelius; Nir Giladi; Karen S Marder; Susan B Bressman
Journal:  Neurology       Date:  2022-06-03       Impact factor: 11.800

4.  Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.

Authors:  Ming Cao; Zhu-Qin Gu; Yuan Li; Hui Zhang; Xiao-Juan Dan; Shan-Shan Cen; Da-Wei Li; Piu Chan
Journal:  Neurosci Bull       Date:  2016-10-03       Impact factor: 5.203

Review 5.  Olfactory Dysfunction in Neurodegenerative Diseases.

Authors:  Concepció Marin; Dolores Vilas; Cristóbal Langdon; Isam Alobid; Mauricio López-Chacón; Antje Haehner; Thomas Hummel; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-15       Impact factor: 4.806

Review 6.  Olfactory dysfunction in Parkinson disease.

Authors:  Richard L Doty
Journal:  Nat Rev Neurol       Date:  2012-05-15       Impact factor: 42.937

7.  Olfaction in Homozygous and Heterozygous SYNJ1 Arg258Gln Mutation Carriers.

Authors:  Marina Picillo; Anna De Rosa; Maria Teresa Pellecchia; Chiara Criscuolo; Marianna Amboni; Roberto Erro; Vincenzo Bonifati; Giuseppe De Michele; Paolo Barone
Journal:  Mov Disord Clin Pract       Date:  2015-07-25

8.  Screening for VPS35 mutations in Parkinson's disease.

Authors:  Una-Marie Sheerin; Gavin Charlesworth; Jose Bras; Rita Guerreiro; Kailash Bhatia; Thomas Foltynie; Patricia Limousin; Laura Silveira-Moriyama; Andrew Lees; Nicholas Wood
Journal:  Neurobiol Aging       Date:  2011-12-07       Impact factor: 4.673

Review 9.  LRRK2: cause, risk, and mechanism.

Authors:  Coro Paisán-Ruiz; Patrick A Lewis; Andrew B Singleton
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

10.  Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?

Authors:  Rachel Saunders-Pullman; Anat Mirelman; Cuiling Wang; Roy N Alcalay; Marta San Luciano; Robert Ortega; Deborah Raymond; Helen Mejia-Santana; Laurie Ozelius; Lorraine Clark; Avi Orr-Utreger; Karen Marder; Nir Giladi; Susan B Bressman
Journal:  Ann Clin Transl Neurol       Date:  2014-09-30       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.